Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) popped in on a high volume green day. Volume on 06-Jun-19 came in at 234388 contracts. The daily trading volume has averaged 199660 shares a day in past 5 days. The first sale was made at $1.25 but later the stock became weaker, and closed with a gain of 14.8%. It was last traded at $1.43 apiece.Titan Pharmaceuticals, Inc. (TTNP): Outperform Candidate With 595.8% Upside Potential
Titan Pharmaceuticals, Inc. is maintained at an average outperform rating by 1 stock analysts, and there are at least 9.15% of shares outstanding that are currently legally short sold. The shares went down by -12.5% in value last month. Year-to-date it jumped 7.25%. Analysts are turning out to be more optimistic than before, with 1 of analysts who cover Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) advice adding it to buy candidate list. Wall Street experts also assign a $9.95 price target on Titan Pharmaceuticals, Inc., pointing towards a 595.8% rally from current levels. The stock is trading for about -79.2% less than its 52-week high.
Titan Pharmaceuticals, Inc. (TTNP) remained unsuccessful in beating the consensus-estimated -$0.26 as it actually earned -$0.34 per share in its last reported financial results. Revenue, on the other hand, scored -11.29% growth from the previous quarter, coming up with $1.1 million.TTNP Adds 23.71% In A Week
This company shares (TTNP) so far managed to recover 39.05% since collapsing to its 52-week low. Over a week, it has seen its stock price volatility to stay at 9.11% while widening the period to a month, volatility was 7.76%. The share price has already crossed its 20 days moving average, floating at a distance of 0.22% and sits -9.36% lower versus its 50 days moving average. When looking at the past five sessions, the stock returned 23.71% gains and is down by -27.24% compared with its 200-day moving average of $1.158. Also, Titan Pharmaceuticals, Inc. (TTNP) needs to overturn a -72.19% decrease it experienced over the past twelve months.
As regular trading ended, Marinus Pharmaceuticals, Inc. (MRNS) stock brought in a -$0.32 drop to $4.3. The day started at a price of $4.61 but then traded as high as $4.62 before giving part of the gains back. As for this week, analysts appear content to stick with their bright outlook with the consensus call at 1.6. Marinus Pharmaceuticals, Inc. is given 4 buy-equivalent recommendations, 0 sells and 1 holds. The company shares sank -59.2% from their peak of $10.54 and now has a $225.6 million market value of equity.Marinus Pharmaceuticals, Inc. Could Grow 273.49% More
MRNS’s mean recommendation on Reuter’s scale presents no change from 1.62 thirty days ago to 1.62 now, which indicates a buy consensus from the analyst community. They see Marinus Pharmaceuticals, Inc. (MRNS) price hitting a mean target of $16.06 a share, meaning the stock still has potential that could lift the price another 273.49% . Also, the recent close suggests the stock is underpriced by 469.77% compared to the most bullish target.
The company had seen its current volume reaching at 220597 shares in the last trade. That compares with the recent volume average of 364860. At the close of regular trading, its last week’s stock price volatility was 6.55% which for the month reaches 6.22%. Marinus Pharmaceuticals, Inc. dipped to as low as $4.26 throughout the day and has returned 49.83% in this year. At one point in the past year, the shares traded as low as $2.36 but has recovered 82.2% since then. [T4]